NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support **10 Feb 2015**

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.*

Important notices

- **NIH Interim General Grant Conditions Implementing New HHS Grants Regulations (Uniform Guidance) (NOT-OD-15-065)**

1. Title: Lifespan Human Connectome Project: Aging

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-AG-16-004) **Type:** UO1
Application Due Date: June 15, 2015, by 5:00 PM local time of applicant organization.
Purpose: This FOA is issued as an initiative of the NIH Blueprint for Neuroscience Research. The Neuroscience Blueprint is a collaborative framework through which 15 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.ni h.gov/). The Neuroscience Blueprint is supporting a Lifespan Human Connectome Project (L-HCP) to extend the Human Connectome Project (HCP) (http://www.neuroscienceblueprint.nih.gov/connectome) to map connectivity in the developing, adult, and aging human brain. The goal of this FOA is solicit grant applications that propose to extend the experimental protocols developed through the HCP to ***middle-age and elderly adults*** to investigate the structural and functional changes that occur in the brain during typical aging. A companion FOA is soliciting applications that apply the HCP protocols to children and adolescents to explore changes that occur during typical development.
Budget: Application budgets need to reflect the actual needs of the proposed project, but are limited to $2 million total cost in the first year and $4 million/year total cost in subsequent years. The maximum project period is 4 years.

2. Title: Lifespan Human Connectome Project: Development

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-MH-16-150) **Type:** U01
Application Due Date: June 15, 2015, by 5:00 PM local time of applicant organization.
Purpose: This Funding Opportunity Announcement (FOA) is issued as an initiative of the NIH Blueprint for Neuroscience Research. The Neuroscience Blueprint is a collaborative framework through which 15 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). The Neuroscience Blueprint is supporting a Lifespan Human Connectome Project (L-HCP) to extend the Human Connectome Project (HCP) (http://www.neuroscienceblueprint.nih.gov/connectome) to map connectivity in the developing, adult, and aging human brain. The goal of this FOA is to solicit grant applications that propose to extend the experimental protocols developed through the HCP to ***children and adolescents*** to investigate the structural and functional changes that occur in the brain during typical development. A companion FOA is soliciting applications that apply the HCP protocols to middle age and elderly adults to explore changes that occur during normal aging.
Budget: Application budgets need to reflect the actual needs of the proposed project, but are limited to $2 million total cost in the first year and $4 million/year total cost in subsequent years. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

3. Title: Developing Technologies and Tools to Monitor HIV Brain Reservoirs and How They May be Altered by Exposure to Substances of Abuse

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-DA-15-018) **Type:** R21/R33
Application Due Date: April 10, 2015, by 5:00 PM local time of applicant organization
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support projects developing technologies and tools to detect and quantify HIV brain reservoirs and how they may be altered by exposure to substances of abuse.
Budget: Application budgets need to reflect the actual needs of the proposed project. The budget for the R21 cannot exceed $250k direct costs per year. The budget for the R33 phase cannot exceed $500k direct costs per year. The scope of the proposed project should determine the project period. The maximum period of the combined R21 and R33 phases is 5 years, with up to 3 years for the R21 phase and up to 2 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

NIH National Institutes of Health
Turning Discovery Into Health

4. Title: Gene-Environment Interplay in Substance Use Disorders

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PA-15-110) **Type:** RO1
(PA-15-112) R21

Application Due Date: June 5, Oct 5 2015 by 5:00 PM local time of applicant organization.

Purpose: This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates. Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field. Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies.

Budget: **RO1**: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Brief definitions of some NIH grant mechanisms: **comprehensive list of extramural grant and cooperative agreement activity codes**

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

UH2/UH3 - Phase Innovation Awards Cooperative Agreement: Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete **Glossary and acronym list of NIH Terms**

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa de Vries*** • Tel: 9838 • Email: **cdevries@sun.ac.za**